Otonomy Suspends Development of Lead Drug After Phase III Flop, Stock Plunges Post author:Sam Post published:August 29, 2017 Post category:BioPharma August 30, 2017By Alex Keown, BioSpace… Source: BioSpace You Might Also Like Once-Prominent Bay Area Biotech VC, Faces Up to 30 Years in Prison September 20, 2017 MorphoSys AG Reports Outcome Of Annual General Meeting 2017 May 16, 2017 Pharming Group Report On Preliminary Financial Results For 2016 March 8, 2017
